Esperion Therapeutics Inc [ESPR] stock prices are up 1.52% to $4.01 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ESPR shares have gain 35.93% over the last week, with a monthly amount glided 39.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Esperion Therapeutics Inc [NASDAQ: ESPR] stock has seen the most recent analyst activity on November 25, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $9. Previously, Goldman started tracking the stock with Neutral rating on December 18, 2024, and set its price target to $4. On December 17, 2024, Cantor Fitzgerald initiated with an Overweight rating and assigned a price target of $8 on the stock. BofA Securities downgraded its rating to a Underperform but stick to its price target of $2.50 on June 20, 2024. BofA Securities downgraded its rating to a Neutral. In a note dated August 01, 2023, Northland Capital upgraded a Market Perform rating on this stock.
The stock price of Esperion Therapeutics Inc [ESPR] has been fluctuating between $0.69 and $4.02 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Esperion Therapeutics Inc [NASDAQ: ESPR] shares were valued at $4.01 at the most recent close of the market. An investor can expect a potential return of 124.44% based on the average ESPR price forecast.
Analyzing the ESPR fundamentals
The Esperion Therapeutics Inc [NASDAQ:ESPR] reported sales of 303.80M for trailing twelve months, representing a surge of 69.10%. Gross Profit Margin for this corporation currently stands at 0.14% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.32%, and Net Profit Margin reading is -0.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is 0.23 and Total Capital is -4.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.92 points at the first support level, and at 3.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.06, and for the 2nd resistance point, it is at 4.11.
Ratios To Look Out For
It’s worth pointing out that Esperion Therapeutics Inc [NASDAQ:ESPR]’s Current Ratio is 1.15. On the other hand, the Quick Ratio is 0.76, and the Cash Ratio is 0.26. Considering the valuation of this stock, the price to sales ratio is 3.16.
Transactions by insiders
Recent insider trading involved Looker Benjamin, Officer, that happened on Oct 17 ’25 when 1248.0 shares were purchased. General Counsel, Looker Benjamin completed a deal on Sep 17 ’25 to sell 6267.0 shares. Meanwhile, President and CEO Koenig Sheldon L. sold 28427.0 shares on Sep 17 ’25.
